Clinical TrialMay 19, 2026, 05:32 PM
Monopar ALXN1840 Phase 2 Improves Copper Balance in Wilson Disease
AI Summary
Monopar Therapeutics announced the publication of positive Phase 2 ALXN1840-WD-204 study results in Hepatology Communications. The study demonstrated that ALXN1840 (tiomolibdate choline) produced a rapid, statistically significant, and sustained improvement in daily copper balance in patients with Wilson disease, primarily driven by increased fecal copper excretion. The drug was generally well tolerated with no serious adverse events, and these improvements were observed even in patients with long prior treatment durations, suggesting its ability to mobilize residual copper.
Key Highlights
- Monopar announced publication of Phase 2 ALXN1840 study results in Hepatology Communications.
- ALXN1840 significantly improved daily copper balance in Wilson disease patients.
- Cumulative mean decrease in copper balance of -6.08 mg over 21 days from baseline.
- Mean daily copper balance change of -0.37 mg (p=0.005) during 15 mg/day treatment.
- Approximately 50% increase in daily fecal copper output-to-intake ratio (p=0.041).
- Immediate increases in plasma total copper and non-ceruloplasmin-bound copper observed.
- ALXN1840 was generally well tolerated with no serious adverse events reported.
- Improvements occurred in patients with a mean of 16 years of prior standard of care treatment.
Price Impact
More from MNPR